000K utf8 1100 $c2011 1500 eng 2050 urn:nbn:de:gbv:8-diss-61619 3000 Mohseni Nodehi, Sahar 4000 Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96$hChristian-Albrechts-Universität zu Kiel [Mohseni Nodehi, Sahar] 4030 Kiel$nChristian-Albrechts-Universität zu Kiel 4209 Regardless of progress in the therapy of AML, there is no long-term cure for about 70% of AML patients. Leukemic stem cells seem to be an important key for the perpetuation of AML.Most currently used chemotherapeutic agents are not able to eliminate AML-LSCs. The combination of conventional therapies with AML-LSCs-directed therapies may eventually lead to a cure for AML patients.Recently expression of CD96 was reported on AML-LSCs, while only very low expression levels were found on normal HSCs.Therefore CD96 may be an excellent target antigen for therapeutic antibodies directed against AML stem cells and blasts. 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8-diss-61619$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/diss_mods_00006161 5051 500 5550 ADCC 5550 affinity maturation 5550 AML-LSC 5550 antibody-engineering 5550 CD96